Bispecific antibodies (bispecifics) can simultaneously target two distinct antigens or epitopes, offering novel therapeutic strategies such as enhancing immune cell targeting of cancer cells or ...

Want to share this FREE webinar with a colleague? Fill out the form below, and we shall send your colleague an invitation to the "Bispecific Antibodies: Early Discovery to Preclinical Development" ...

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc. is pleased to announce the launch of its Rapid Bispecific Antibody Discovery Services. Utilizing Invenra’s B-Body® Bispecific Platform, the streamlined ...

New analysis from the Antibody Collaboration and Licensing Deals report shows pharma committing record capital to differentiated antibody assets and the technologies that generate them.Dublin, June 11 ...

VERAXA Biotech AG, a developer of innovative cancer therapies, has announced a partnership with OmniAb, Inc. to create a bispecific antibody drug conjugate (bsADC) program aimed at treating solid ...

The demand for sophisticated biologics is soaring, but discovery pipelines often lag. Many biopharmaceutical companies struggle to discover and optimize next-generation biologics such as bispecific ...

You don't want to miss this! To permanently access this Infographic for free, fill out the short form below. Successful bispecific antibody discovery hinges on early decisions that reduce risk, ...

Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that ...

Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its partner company with Aditum Bio, Oblenio Bio (“Oblenio”), has successfully closed an ...